Zobrazeno 1 - 8
of 8
pro vyhledávání: '"Ann Leighton-Swayze"'
Autor:
José Baselga, Scot Ebbinghaus, Yang Song, Ann Leighton-Swayze, Richard A. Klinghoffer, Jason Frazier, Youyuan Xu, Sharda Jha, Christopher G. Winter, Theresa Zhang, Brian B. Haines, Desamparados Roda, Irene Braña, Mark N. Stein, Andrés Cervantes, Johanna C. Bendell, Sriram Sathyanarayanan, Serena Di Cosimo
Supplementary Table 1. Hits from the dalotuzumab enhancer screen. Supplementary Table 2. Patient and disease characteristics. Supplementary Table 3. Summary of dose-limiting toxicities. Supplementary Table 4. Summary of clinical efficacy in breast ca
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::025a26d870c9fda45bccdde6460658d4
https://doi.org/10.1158/1078-0432.22454814.v1
https://doi.org/10.1158/1078-0432.22454814.v1
Autor:
José Baselga, Scot Ebbinghaus, Yang Song, Ann Leighton-Swayze, Richard A. Klinghoffer, Jason Frazier, Youyuan Xu, Sharda Jha, Christopher G. Winter, Theresa Zhang, Brian B. Haines, Desamparados Roda, Irene Braña, Mark N. Stein, Andrés Cervantes, Johanna C. Bendell, Sriram Sathyanarayanan, Serena Di Cosimo
Supplementary Figure 1. Treatment and pharmacodynamic assessment schedules.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::78f2f3ed94a6bd56e383704d713371c7
https://doi.org/10.1158/1078-0432.22454826
https://doi.org/10.1158/1078-0432.22454826
Autor:
José Baselga, Scot Ebbinghaus, Yang Song, Ann Leighton-Swayze, Richard A. Klinghoffer, Jason Frazier, Youyuan Xu, Sharda Jha, Christopher G. Winter, Theresa Zhang, Brian B. Haines, Desamparados Roda, Irene Braña, Mark N. Stein, Andrés Cervantes, Johanna C. Bendell, Sriram Sathyanarayanan, Serena Di Cosimo
Purpose: Mammalian target of rapamycin (mTOR) inhibition activates compensatory insulin–like growth factor receptor (IGFR) signaling. We evaluated the ridaforolimus (mTOR inhibitor) and dalotuzumab (anti-IGF1R antibody) combination.Experimental Des
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::32284213cd5fddddd74502300a970e96
https://doi.org/10.1158/1078-0432.c.6522843.v1
https://doi.org/10.1158/1078-0432.c.6522843.v1
Autor:
José Baselga, Scot Ebbinghaus, Yang Song, Ann Leighton-Swayze, Richard A. Klinghoffer, Jason Frazier, Youyuan Xu, Sharda Jha, Christopher G. Winter, Theresa Zhang, Brian B. Haines, Desamparados Roda, Irene Braña, Mark N. Stein, Andrés Cervantes, Johanna C. Bendell, Sriram Sathyanarayanan, Serena Di Cosimo
Supplementary Figure 3. Change in Ki67 levels with ridaforolimus and dalotuzumab combination therapy
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cad0fb5dc49be6c69df85bf35b08f9e5
https://doi.org/10.1158/1078-0432.22454820.v1
https://doi.org/10.1158/1078-0432.22454820.v1
Autor:
José Baselga, Scot Ebbinghaus, Yang Song, Ann Leighton-Swayze, Richard A. Klinghoffer, Jason Frazier, Youyuan Xu, Sharda Jha, Christopher G. Winter, Theresa Zhang, Brian B. Haines, Desamparados Roda, Irene Braña, Mark N. Stein, Andrés Cervantes, Johanna C. Bendell, Sriram Sathyanarayanan, Serena Di Cosimo
Supplementary Figure 2. Combination therapy with ridaforolimus and dalotuzumab potentiates PI3K pathway inhibition and blocks cancer cell proliferation
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5f314e14c255ba8dd5f745d3b61795db
https://doi.org/10.1158/1078-0432.22454823
https://doi.org/10.1158/1078-0432.22454823
Autor:
José Baselga, Scot Ebbinghaus, Yang Song, Ann Leighton-Swayze, Richard A. Klinghoffer, Jason Frazier, Youyuan Xu, Sharda Jha, Christopher G. Winter, Theresa Zhang, Brian B. Haines, Desamparados Roda, Irene Braña, Mark N. Stein, Andrés Cervantes, Johanna C. Bendell, Sriram Sathyanarayanan, Serena Di Cosimo
Supplementary Figure 4. Responder biomarker hypothesis for ridaforolimus and dalotuzumab?based therapy
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0dddbb7e30954b9b22c2501410b9fea0
https://doi.org/10.1158/1078-0432.22454817.v1
https://doi.org/10.1158/1078-0432.22454817.v1
Autor:
Jason Alan Chesney, Adam J. Schoenfeld, Trisha Wise-Draper, Ammar Sukari, Kai He, Friedrich Graf Finckenstein, Parameswaran Hari, Madan Jagasia, Selda Samakoglu, Ann Leighton-Swayze, Guang Chen, Yong Ki Hong
Publikováno v:
Cancer Research. 82:CT130-CT130
Background: Patients with mNSCLC without actionable driver mutations have limited second-line (2L) options after progression on concurrent or sequential front-line immune checkpoint inhibitors (ICI) and platinum-based chemotherapy ± bevacizumab. Ear
Autor:
Andrés Cervantes, Ann Leighton-Swayze, Richard A. Klinghoffer, José Baselga, Scot Ebbinghaus, Sriram Sathyanarayanan, Christopher Winter, Theresa Zhang, Irene Brana, Sharda Jha, Yang Song, Serena Di Cosimo, Johanna C. Bendell, Brian B. Haines, Desamparados Roda, Jason Frazier, Mark N. Stein, Youyuan Xu
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research. 21(1)
Purpose: Mammalian target of rapamycin (mTOR) inhibition activates compensatory insulin–like growth factor receptor (IGFR) signaling. We evaluated the ridaforolimus (mTOR inhibitor) and dalotuzumab (anti-IGF1R antibody) combination. Experimental De